BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 30,000 Shares

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 30,000 shares of BioNTech stock in a transaction on Friday, September 18th. The stock was sold at an average price of $96.22, for a total value of $2,886,600.00. Following the sale, the chief executive officer directly owned 489,209 shares of the company’s stock, valued at $47,071,689.98. This represents a 5.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.60, for a total transaction of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The shares were sold at an average price of $96.09, for a total transaction of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $96.49, for a total transaction of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The stock was sold at an average price of $99.45, for a total transaction of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total transaction of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total transaction of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The stock was sold at an average price of $99.20, for a total transaction of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total transaction of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $102.85, for a total value of $4,628,250.00.

BioNTech Price Performance

NASDAQ:BNTX traded down $2.60 during trading hours on Friday, reaching $96.06. 1,150,292 shares of the company were exchanged, compared to its average volume of 1,102,362. The company has a market capitalization of $24.29 billion, a P/E ratio of -12.27 and a beta of 1.29. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. The business has a 50 day moving average of $97.29 and a 200 day moving average of $94.92.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The company had revenue of $122.31 million during the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The firm’s revenue for the quarter was down 59.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.60) EPS. Research analysts forecast that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.

Institutional Investors Weigh In On BioNTech

A number of hedge funds have recently made changes to their positions in BNTX. Larson Financial Group LLC grew its stake in shares of BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after buying an additional 127 shares during the last quarter. AlphaCentric Advisors LLC increased its holdings in shares of BioNTech by 5.7% during the first quarter. AlphaCentric Advisors LLC now owns 5,616 shares of the company’s stock worth $499,000 after buying an additional 305 shares in the last quarter. USS Investment Management Ltd lifted its stake in shares of BioNTech by 1.2% in the 1st quarter. USS Investment Management Ltd now owns 32,577 shares of the company’s stock valued at $2,854,000 after acquiring an additional 382 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of BioNTech in the 2nd quarter valued at $39,000. Finally, Marks Group Wealth Management Inc boosted its holdings in shares of BioNTech by 16.0% during the 1st quarter. Marks Group Wealth Management Inc now owns 3,454 shares of the company’s stock valued at $307,000 after acquiring an additional 476 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Jefferies Financial Group restated a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. UBS Group reiterated a “buy” rating on shares of BioNTech in a research report on Wednesday. BMO Capital Markets cut shares of BioNTech from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $128.00 to $105.00 in a research note on Tuesday, September 8th. Sanford C. Bernstein restated a “market perform” rating on shares of BioNTech in a research report on Friday, June 5th. Finally, Wall Street Zen downgraded shares of BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $126.00.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.